Poor prognosis in pancreatic cancer is due in part to poor response to the current standard of care (gemcitabine, a cytidine nucloeside analog). Our preliminary data establish a novel, widely-prevalent mechanism of resistance to fluoropyrimidines whereby the Hypoxia-Inducible Factor1 (HIF1) alpha-induced glycolytic flux leads to a corresponding increase in the pyrimidine biosynthetic pathway to enhance the intrinsic levels of cytidine. Such increased levels of cytidine/dCTP diminish the effective levels of gemcitabine and 5FU (in FOLFIRINOX) through molecular competition or dilution. Our data also indicate existance of a bidirectional tumor-stromal metabolite flux that may facilitate tumor/stromal cell survival under low nutrient conditions, promote desmoplasia, increase metabolite flux into pyrimidine biosynthetic pathway, and result in decreased chemotherapy sensitivity. Thus, we propose to determine if combining gemcitabine/FOLFIRINOX therapies with digoxin (to target HIF1 alpha) or Leflunomide (to target pyrimidine biosynthesis) will diminish fluoropyrimidine therapy resistance in pancreatic cancer patients (AIM 1). Additionally, we will employ 18FFDG- PET imaging in pancreatic cancer patients to predict the resistance status of the tumor against pyrimidine analogs (AIM1). We will also investigate if cytidine levels in pancreatic tumors/biofluids may serve as potential biomarkers for chemotherapy responsiveness in pancreatic cancer patients (AIM2). Furthermore, we will investigate if tumor-stromal metabolite exchange facilitates stromal cell survival and desmoplasia in tumor models, and increased pyrimidine biosynthesis and diminished gemcitabine responsiveness in tumor cells (AIM3). We predict that our proposed improvement to current chemotherapy strategies will improve survival in pancreatic cancer patients by increasing the efficacy and/or decreasing the toxicity, by requiring smaller doses, of chemotherapy strategies that employ gemcitabine and/or 5FU.
Here, we will investigate if targeting a novel metabolic pathway of chemoresistance will be efficacious in improving responsiveness to fluoropyrimidine-based therapies in pancreatic tumors. We will investigate imaging/biomarker approaches for predicting response and determine if novel combinations of approved chemotherapy agents with gemcitabine or FOLFIRINOX will improve survival in pancreatic cancer.
|Pai, Priya; Rachagani, Satyanarayana; Dhawan, Punita et al. (2016) Mucins and Wnt/Î²-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis 37:223-32|
|Gunda, Venugopal; Yu, Fang; Singh, Pankaj K (2016) Validation of Metabolic Alterations in Microscale Cell Culture Lysates Using Hydrophilic Interaction Liquid Chromatography (HILIC)-Tandem Mass Spectrometry-Based Metabolomics. PLoS One 11:e0154416|
|Vaz, Arokia Priyanka; Deb, Shonali; Rachagani, Satyanarayana et al. (2016) Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Oncotarget 7:3317-31|
|Hein, Ashley L; Seshacharyulu, Parthasarathy; Rachagani, Satyanarayana et al. (2016) PR55Î± Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res 76:2243-53|
|Wang, Yan; Kumar, Sushil; Rachagani, Satyanarayana et al. (2016) Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis. Biomaterials 101:108-20|
|Veldkamp, Christopher T; Koplinski, Chad A; Jensen, Davin R et al. (2016) Production of Recombinant Chemokines and Validation of Refolding. Methods Enzymol 570:539-65|
|Pai, Priya; Rachagani, Satyanarayana; Lakshmanan, Imayavaramban et al. (2016) The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Mol Oncol 10:224-39|
|Krishn, Shiv Ram; Kaur, Sukhwinder; Smith, Lynette M et al. (2016) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. Cancer Lett 374:304-14|
|Hein, A L; Post, C M; Sheinin, Y M et al. (2016) RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene 35:6319-6329|
|Fink, Darci M; Steele, Maria M; Hollingsworth, Michael A (2016) The lymphatic system and pancreatic cancer. Cancer Lett 381:217-36|
Showing the most recent 10 out of 137 publications